Merck discontinues Phase 3 trial for lung cancer combo drug EP News Bureau Aug 9, 2024 When compared to patients in the control arm, patients in the vibostolimab and pembrolizumab fixed-dose combination arm…
Early research suggests Merck cancer drug may target dormant HIV Reuters Jan 29, 2022 Antiretroviral treatments now allow many HIV patients to lead normal lives, but the drugs do not completely remove the virus from…
US FDA approves KEYTRUDA from Merck for adults with relapsed or refractory cHL EP News Bureau Oct 15, 2020 KEYTRUDA is the first anti-PD-1 therapy approved for adult patients with relapsed or refractory cHL after frontline therapy
